Table 5.
Heart Failure, Takotsubo Cardiomyopathy, and Mechanical Thrombectomy
| Reference | Study type | Total No. of patients | Age, y | Patients treated with MT, n (%) | Patients with mRS score 0–2 at 90 d, n (%) | Patients with mRS score of 6 at 90 d, n (%) | Patients with sICH, n (%) | Patients with successful recanalization (mTICI 2b–3), n (%) | Summary of study findings |
|---|---|---|---|---|---|---|---|---|---|
| Schnieder et al 2019 99 | Observational study on prospective single‐center stroke registry | 373 Patients with AIS, of whom 90 (24%) with HF |
No HF: median, 73 (IQR: 63–83) HF: median, 77 (IQR: 70–84)* |
373 (100.0) |
No HF: 105 (48.2) HF: 32 (43.8) |
No HF: 17 (7.4) HF: 9 (11) |
No HF: 2 (1) HF: 3 (4.4) |
No HF: 175 (76.4) HF: 63 (75.9) |
No significant differences in study outcomes between patients with vs without HF |
| Gentile et al 2023 101 | Observational study on multicenter registry | 8924 Patients with AIS, of whom 642 (7.2%) with HF |
No HF: median, 73.8 (IQR: 62.9–80.8) HF: median, 77.1 (IQR: 68.2–82.8)* |
8924 (100.0) |
No HF: 3992 (48.2) HF: 234 (36.4)* |
No HF: 1530 (18.5) HF: 197 (30.7)* |
No HF: 648 (8.3) HF: 45 (7.6) |
No HF: 6398 (78.1) HF: 488 (76.9) |
Worse 90‐d functional outcomes and higher mortality rates than patients with vs without HF |
| Siedler et al 2019 102 | Observational study on single‐center registry | 1209 Patients with AIS, of whom 378 (31.3%) with HF |
No HF: mean, 69.9 (±SD: 13.5) HF: mean, 76.1 (±SD: 12.1)* |
No HF: 155 (18) HF: 88 (24) |
No HF: 51% HF: 35%* |
No HF: 9% HF: 20%* |
No HF: 3% HF: 7% |
No HF: 87% HF: 92% |
Patients with HF had worse 90‐d functional outcomes and higher mortality rates than patients with vs without HF (also in the matched cohort) |
| Tan et al 2021 103 | Retrospective study on 6 international stroke registries | 440 Patients with AIS, of whom 101 (23.0%) with HF |
No HF: mean, 67.0 (±SD: 13.2) HF: mean, 63.5 (±SD: 13.8)* |
440 (100.0) |
No HF: 161 (48.1) HF: 32 (32.0)* |
No HF: 19 (5.7) HF: 21 (21.0)* |
No HF: 35 (10.0) HF: 15 (15.0) |
No HF: 289 (85.3) HF: 87 (87.0) |
Worse 90‐d functional outcomes and higher mortality rates than patients with vs without HF |
| Pana et al 2021 104 | Observational study on publicly available national stroke registry | 33 173 Patients with AIS undergoing EVT, of whom 2376 (7.2%) with HF, 4390 (13.2%) with HF and AF, and 10 826 (32.6%) with AF |
No HF/AF: median, 61 (IQR: 51–72) AF: median, 76 (IQR: 67–82) HF: median, 67 (IQR: 56–77) HF+AF: median, 77 (IQR: 66–83)* |
33 173 (100.0) | NA | NA | NA |
No HF/AF: 3939 (25.3) AF: 3093 (28.6) HF: 596 (25.1) HF+AF: 1268 (28.9) |
No difference in reperfusion rates in patients with vs without HF |
| Y‐Hassan et al 2019 106 | Case report | 1 | 67 | 1 (100.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | MT with TCM is effective and safe |
| Riva et al 2021 107 | Case report | 1 | 78 | 1 (100.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | MT with TCM is effective and safe |
| Yamasaki et al 2021 108 | Case report | 1 | 73 | 1 (100.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | MT with TCM is effective and safe |
| Nagendra et al 2023 109 | Case report | 1 | 67 | 1 (100.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | MT with TCM is effective and safe |
AF indicates atrial fibrillation; AIS, acute ischemic stroke; HF, heart failure; EVT, endovascular treatment; IQR, interquartile range; mRS, modified Rankin Scale; MT, mechanical thrombectomy; mTICI, modified Treatment in Cerebral Ischemia; NA, not available; sICH, symptomatic intracranial hemorrhage; TCM, Takotsubo cardiomyopathy.
Significantly different at P<0.05.